Janssen Pharmaceutica describes new MAP3K14 inhibitors for cancer
Dec. 7, 2023
Janssen Pharmaceutica NV had disclosed new pyrrolidinone derivatives acting as NF-κB-inducing kinase (NIK; MAP3K14) inhibitors and reported to be useful for the treatment of cancer.